Halozyme Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 373
- Market Cap
- $8B
- Website
- http://www.halozyme.com
- Introduction
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and a...
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 28
- Registration Number
- NCT01453153
- Locations
- 🇺🇸
UMDNJ - New Jersey Medical School, Newark, New Jersey, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States
🇺🇸NSLIJ Health System, Monter Cancer Center, New Hyde Park, New York, United States
Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)
- Conditions
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT01275131
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 132
- Registration Number
- NCT01194258
- Locations
- 🇺🇸
Mercury Street Medical, Butte, Montana, United States
🇺🇸UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇺🇸John Muir Physician Network Clinical Research Center, Concord, California, United States
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 135
- Registration Number
- NCT01194245
- Locations
- 🇺🇸
Mercury Street Medical, Butte, Montana, United States
🇺🇸Mid-America Diabetes Associates, Wichita, Kansas, United States
🇺🇸Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT01170897
- Locations
- 🇺🇸
Ramesh K. Ramanathan M.D., Scottsdale, Arizona, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Jeffrey R. Infante, Nashville, Tennessee, United States
A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone
- Conditions
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT00979875
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT00928447
- Locations
- 🇺🇸
Symbio Phase I Unit, Saint Anthony Memorial Research Center, Michigan City, Indiana, United States
Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Interventions
- First Posted Date
- 2009-06-09
- Last Posted Date
- 2014-08-18
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT00916357
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2009-04-17
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT00883558
- Locations
- 🇺🇸
UNC Diabetes Care Center/Highgate Specialty Center, Durham, North Carolina, United States
🇺🇸West Olympia Internal Medicine, Olympia, Washington, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone
- Conditions
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT00862849
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States